Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
LEXINGTON, Mass., March 30, 2017 -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists will present data from its IRAK4 kinase inhibitor development candidate, CA-4948, at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 1 – 5, 2017 in Washington, D.C. Curis has exclusive license to CA-4948 under a collaboration agreement with Aurigene established in 2015.
Additional information follows. Abstracts can be accessed at www.aacr.org.
| Poster Presentation | ||
| Date/Time: | Monday, Apr. 3, 2017, 8:00 AM - 12:00 PM | |
| Session Title: | Novel Molecular Targets 1 | |
| Session Category: | Experimental and Molecular Therapeutics | |
| Presentation Title: | Efficacy of the IRAK4 Inhibitor CA-4948 in Patient-Derived Xenograft Models of Diffuse Large B Cell Lymphoma | |
| Abstract Number: | 1168 |
About Curis, Inc.
Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: Company Contact: James E. Dentzer Chief Financial Officer & Chief Administrative Officer 617-503-6500 [email protected] Media Contact: David Schull Russo Partners 212-845-4271 [email protected]
